A preliminary clinical research of neoadjuvant stereotactic body radiotherapy for downstaging and resecting hepatocellular carcinoma with portal vein tumor thrombus and the identification of biomarkers of radiosensitivity

A prospective,single-arm, open-label clinical research of neoadjuvant stereotactic body radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus and the identification of biomarkers of radiosensitivity

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035877

Enrollment

Unknown

Registered

2020-08-19

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heopatocellular carcinoma

Interventions

Case series:neoadjuvant SBRT: 12Gyx3

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients consent to join this trial and sign the Informed Consent Form; 2. Male or female aged between 18-75 years; 3. Clinically or pathologically confirmed hepatocellular carcinoma; 4. Resectable lesion with type II/III portal vein tumor thrombus; 5. Liver function: Child-pugh A; 6. ECOG score:0-1; 7. Anticipated survival >= 12 weeks; 8. Without severe systemic disease.

Exclusion criteria

Exclusion criteria: 1. a history of other malignancy in five years; 2. underwent other invasive therapies.

Design outcomes

Primary

Measure	Time frame
Disease Free Survival;	—

Secondary

Measure	Time frame
Objective Response Rate;Overall survival;	—

Countries

China

Contacts

Public ContactXubiao Wei

Oriental Hepatobiliary Surgery Hospital

weixubiao@hotmail.com+86 13636354249

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026